Business Wire

CA-RAFTR

16.3.2020 19:02:07 CET | Business Wire | Press release

Share
Raftr to Offer Instant Communication Platform Free of Charge to Colleges & Universities

Silicon Valley-based higher ed tech company Raftr announced today that it will offer its messaging and notifications platform free of charge through July 1, 2020 to colleges and universities, many of which are facing disruption and dislocation as a result of COVID-19 concerns. Each institution’s network is entirely private, limited to that community’s constituents.

The app facilitates immediate and direct communication between college administrations and their students in a mobile-first platform, enabling instant direct messaging to students’ mobile devices.

“Our partner institutions are facing a rapidly evolving COVID-19 outbreak, forcing unprecedented disruption on campuses and in remote learning environments,” Raftr Founder & CEO Sue Decker says. “The right thing to do is to offer our support. Raftr enables immediate communication between universities and their students, faculty, staff, and even parents, anywhere in the world. Exceptionally fast to implement, the interactive, flexible and coordinated communication platform can stand-alone or supplement email communication.”

Raftr enables group administrators to send custom push notifications directly to students’ and parents’ mobile devices, highlighting important updates about issues related to COVID-19, including online learning, study abroad cancellations or updates, academic information, and more.

Key features and customization options for different campus constituents include:

Administration:

  • Public and private chat channels for sharing information, and Q&A in real time.
  • Optional automatic posting of existing COVID-19 updates from authenticated sources, including CDC, the WHO, and/or existing university sources.
  • Curated organization of all past communications for easy discovery and access.

Faculty:

  • Ability to host real-time, virtual discussions and “office hours” in private channels for online courses, easily discoverable by students.
  • Creation of an online lecture calendar with days / times of courses and ability to link directly to Zoom, Hangouts, or other online learning platforms.
  • Direct and group chat options to stay connected to students one-on-one or in class settings.
  • Ability to add links to important teaching materials.

Students:

  • Creation of digital communities that mirror those on campus, including classes, student groups, social groups, and volunteer organizations.
  • Ability to create unlimited public or private groups to maintain student organization communication and planning.
  • Access to group chats, topic channels, direct messaging, photos & videos, polls and more.

Decker says the free use of the platform will be granted through July 1. To be eligible, administrators are asked to submit a request to enable their community and attend a one-hour online training session for any staff members who will be posting updates in the platform. Those staff members will be given access to Raftr ProTools, including the ability to send custom push notifications with important updates.

Online Request Form
Submit a request

Connect on Social
Twitter
LinkedIn
Facebook

About Raftr

Raftr promotes the power of belonging by building dynamic and safe digital communities through an intuitive student-centric communication platform. Each enabled school’s experience will be accessible only by that institution’s students, faculty, staff and parents, creating a private, curated, and trusted network. Raftr’s solutions cover every stage of undergraduate and alumni life, with packages for News & Events, Residence Life, Club & Groups / Academic Departments, and Orientation. The platform is available via mobile applications and website, and primary features include events, messaging, push notifications, polls and more. Additional information is available at https://pro.raftr.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/raftr.getcurrent/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release

Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye